Medical management of chemotherapy-induced peripheral neuropathy: a concise review focusing on the past 5 years

Abstract

ABSTRACT Even though chemotherapy has improved survival in patients with different malignancies, it has short-term side effects as well as toxicity in survivors. Chemotherapy-induced peripheral neuropathy (CIPN) is encountered with neurotoxic chemotherapy agents. It has proven difficult to prevent and, once it is already established, management becomes more challenging. Rationale for medications used to treat CIPN are based on extrapolation of their efficacy in other types of neuropathic pain, whereas duloxetine is the only medication that has a moderate strength of recommendation after a phase III double-blind, randomized controlled trial was published on treatment of CIPN.